acetaminophen has been researched along with Hepatitis, Viral, Human in 50 studies
Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.
paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.
Hepatitis, Viral, Human: INFLAMMATION of the LIVER in humans due to infection by VIRUSES. There are several significant types of human viral hepatitis with infection caused by enteric-transmission (HEPATITIS A; HEPATITIS E) or blood transfusion (HEPATITIS B; HEPATITIS C; and HEPATITIS D).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Acetaminophen overdose is the leading cause for calls to Poison Control Centers (>100,000/year) and accounts for more than 56,000 emergency room visits, 2,600 hospitalizations, and an estimated 458 deaths due to acute liver failure each year." | 8.82 | Acetaminophen and the U.S. Acute Liver Failure Study Group: lowering the risks of hepatic failure. ( Lee, WM, 2004) |
| "A total of 125,505 patients with liver cirrhosis were registered from January 1, 2012 to December 31, 2012." | 5.43 | The Prescription Pattern of Acetaminophen and Non-Steroidal Anti-Inflammatory Drugs in Patients with Liver Cirrhosis. ( An, DS; Cho, M; Han, JH; Heo, J; Hong, YM; Lim, W; Woo, HY; Yoon, KT, 2016) |
| "Acetaminophen overdose is the leading cause for calls to Poison Control Centers (>100,000/year) and accounts for more than 56,000 emergency room visits, 2,600 hospitalizations, and an estimated 458 deaths due to acute liver failure each year." | 4.82 | Acetaminophen and the U.S. Acute Liver Failure Study Group: lowering the risks of hepatic failure. ( Lee, WM, 2004) |
| " NETs depletion improved the liver damage and survival rate in FVH by inhibiting hepatic fibrin deposition and inflammation." | 4.12 | FGL2-MCOLN3-Autophagy Axis-Triggered Neutrophil Extracellular Traps Exacerbate Liver Injury in Fulminant Viral Hepatitis. ( Chen, T; Gao, Q; Hai, S; Han, M; Hu, J; Huang, D; Li, X; Luo, X; Ning, Q; Wang, H; Wang, X; Wu, D; Wu, W; Xi, D; Yan, W; You, J, 2022) |
| "To determine the clinical characteristics of patients with acute liver failure of indeterminate cause and their long-term outcome in comparison with patients with acute liver failure of obvious aetiology (acetaminophen and mushroom poisoning, Budd-Chiari syndrome, acute viral hepatitis) and other controls (idiosyncratic drug reactions, autoimmune hepatitis and Wilson's disease)." | 3.74 | Long-term follow-up of patients with acute liver failure of indeterminate aetiology. ( Bergquist, A; Björnsson, E; Kalaitzakis, E; Wei, G, 2008) |
| "Acute liver failure is a rare condition with high short-term morbidity and mortality." | 2.58 | Classification and Epidemiologic Aspects of Acute Liver Failure. ( Pievsky, D; Pyrsopoulos, NT; Rustgi, N, 2018) |
| "Acute liver failure is a rare disorder with high mortality and resource cost." | 2.46 | Acute liver failure. ( Auzinger, G; Bernal, W; Dhawan, A; Wendon, J, 2010) |
| "Malignancy is an uncommon cause of ALF, and thus imaging studies may not be useful in this setting, but liver biopsy may be beneficial in selected cases." | 2.44 | Epidemiology of acute liver failure. ( Khashab, M; Kwo, PY; Tector, AJ, 2007) |
| "A careful search for the cause of acute liver failure in each case is of value in determining whether there are specific antidotes available and what the prognosis might be." | 2.44 | Etiologies of acute liver failure. ( Lee, WM; Seremba, E, 2008) |
| "Fulminant liver disease, acute liver failure (ALF), is one of the most intriguing and challenging conditions in the entire field of internal medicine." | 2.42 | Fulminant liver disease. ( Lee, WM; Schiødt, FV, 2003) |
| "Clinical descriptions of fulminant hepatic failure as originally reported, along with the subgroups of subfulminant and late onset hepatic failure identified later, are considered in relation to the proposed new classification of hyperacute, acute, and subacute liver failure." | 2.39 | Classification, etiology, and considerations of outcome in acute liver failure. ( Williams, R, 1996) |
| "In the United States, the Acute Liver Failure Study Group (ALFSG) registry lists approximately 11% of cases as of indeterminate etiology (IND-ALF) as determined by the respective local site principal investigator (PI)." | 1.48 | Acute Liver Failure of Indeterminate Etiology: A Comprehensive Systematic Approach by An Expert Committee to Establish Causality. ( Bass, N; Chiu, C; Ganger, DR; James, L; Larson, AM; Lee, WM; Rakela, J; Reuben, A; Rule, J; Stravitz, RT; Sussman, N, 2018) |
| "The term acute liver failure (ALF) is frequently applied as a generic expression to describe patients presenting with or developing an acute episode of liver dysfunction." | 1.46 | EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure. ( Bernardi, M; Cordoba, J; Dhawan, A; Larsen, FS; Manns, M; Samuel, D; Simpson, KJ; Wendon,, J; Yaron, I, 2017) |
| "A total of 125,505 patients with liver cirrhosis were registered from January 1, 2012 to December 31, 2012." | 1.43 | The Prescription Pattern of Acetaminophen and Non-Steroidal Anti-Inflammatory Drugs in Patients with Liver Cirrhosis. ( An, DS; Cho, M; Han, JH; Heo, J; Hong, YM; Lim, W; Woo, HY; Yoon, KT, 2016) |
| "However, brain swelling and marked clinical and EEG suppression are potentially reversible, even though the same findings are associated with a very poor neurological outcome in anoxic-ischemic encephalopathy." | 1.36 | Recovery of awareness after hyperacute hepatic encephalopathy with "flat" EEG, severe brain edema and deep coma. ( Hunter, GR; Young, GB, 2010) |
| " The daily dose did not exceed the therapeutic dosage and the mean was 1." | 1.33 | Influence of acetaminophen at therapeutic doses on surrogate markers of severity of acute viral hepatitis. ( Boujaoude, J; Honein, K; Moucari, R; Sayegh, R; Slim, R; Yaghi, C, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (24.00) | 18.7374 |
| 1990's | 15 (30.00) | 18.2507 |
| 2000's | 10 (20.00) | 29.6817 |
| 2010's | 11 (22.00) | 24.3611 |
| 2020's | 2 (4.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, X | 1 |
| Gao, Q | 1 |
| Wu, W | 1 |
| Hai, S | 1 |
| Hu, J | 1 |
| You, J | 1 |
| Huang, D | 1 |
| Wang, H | 1 |
| Wu, D | 1 |
| Han, M | 1 |
| Xi, D | 1 |
| Yan, W | 1 |
| Chen, T | 1 |
| Luo, X | 1 |
| Ning, Q | 1 |
| Wang, X | 1 |
| Dong, V | 1 |
| Nanchal, R | 1 |
| Karvellas, CJ | 1 |
| Wendon,, J | 1 |
| Cordoba, J | 1 |
| Dhawan, A | 2 |
| Larsen, FS | 1 |
| Manns, M | 1 |
| Samuel, D | 1 |
| Simpson, KJ | 1 |
| Yaron, I | 1 |
| Bernardi, M | 1 |
| Pievsky, D | 1 |
| Rustgi, N | 1 |
| Pyrsopoulos, NT | 1 |
| Ganger, DR | 1 |
| Rule, J | 1 |
| Rakela, J | 1 |
| Bass, N | 1 |
| Reuben, A | 1 |
| Stravitz, RT | 1 |
| Sussman, N | 1 |
| Larson, AM | 1 |
| James, L | 1 |
| Chiu, C | 1 |
| Lee, WM | 6 |
| Rajaram, P | 1 |
| Subramanian, R | 1 |
| Tuncer, C | 1 |
| Oo, YH | 1 |
| Murphy, N | 1 |
| Adams, DH | 1 |
| Lalor, PF | 1 |
| Amathieu, R | 1 |
| Levesque, E | 1 |
| Merle, JC | 1 |
| Chemit, M | 1 |
| Costentin, C | 1 |
| Compagnon, P | 1 |
| Dhonneur, G | 1 |
| Willars, C | 1 |
| Hong, YM | 1 |
| Yoon, KT | 1 |
| Heo, J | 1 |
| Woo, HY | 1 |
| Lim, W | 1 |
| An, DS | 1 |
| Han, JH | 1 |
| Cho, M | 1 |
| Wei, G | 1 |
| Kalaitzakis, E | 1 |
| Bergquist, A | 1 |
| Björnsson, E | 1 |
| Hunter, GR | 1 |
| Young, GB | 1 |
| Bernal, W | 2 |
| Auzinger, G | 1 |
| Wendon, J | 2 |
| Laverty, HG | 1 |
| Antoine, DJ | 1 |
| Benson, C | 1 |
| Chaponda, M | 1 |
| Williams, D | 1 |
| Kevin Park, B | 1 |
| Schiødt, FV | 1 |
| Yaghi, C | 1 |
| Honein, K | 1 |
| Boujaoude, J | 1 |
| Slim, R | 1 |
| Moucari, R | 1 |
| Sayegh, R | 1 |
| Khashab, M | 1 |
| Tector, AJ | 1 |
| Kwo, PY | 1 |
| Polson, J | 1 |
| Seremba, E | 1 |
| Langley, PG | 7 |
| Hughes, RD | 8 |
| Williams, R | 18 |
| Schmid, M | 1 |
| Meliconi, R | 1 |
| Perperas, A | 1 |
| Jensen, D | 1 |
| Alberti, A | 1 |
| McFarlane, IG | 1 |
| Eddleston, AL | 3 |
| Wyke, RJ | 2 |
| Canalese, JC | 1 |
| Gimson, AE | 2 |
| Record, CO | 1 |
| Chase, RA | 1 |
| Appleton, D | 1 |
| Canalese, J | 1 |
| Vergani, D | 1 |
| Izumi, S | 1 |
| Pernambuco, JR | 1 |
| Wendon, JA | 1 |
| Harrison, PM | 2 |
| Keays, R | 1 |
| Bernard, PH | 1 |
| Le Bail, B | 1 |
| Carles, J | 1 |
| Fawaz, R | 1 |
| Balabaud, C | 1 |
| Rosenbaum, J | 1 |
| Bioulac-Sage, P | 1 |
| Miwa, Y | 1 |
| Farzaneh, F | 1 |
| Schiff, ER | 1 |
| Anderson, C | 1 |
| Thabrew, MI | 1 |
| Bowen, DG | 1 |
| Shackel, NA | 1 |
| McCaughan, GW | 1 |
| Ostapowicz, G | 1 |
| Shinzawa, H | 1 |
| Togashi, H | 1 |
| Sugahara, K | 1 |
| Ishibashi, M | 1 |
| Terui, Y | 1 |
| Aoki, M | 1 |
| Mitsuhashi, H | 1 |
| Matsuo, T | 1 |
| Watanabe, H | 1 |
| Abe, T | 1 |
| Ohno, S | 1 |
| Saito, K | 1 |
| Saito, T | 1 |
| Yamada, N | 1 |
| Takahashi, T | 1 |
| Horiuchi, R | 1 |
| Eleftheriou, N | 1 |
| Heathcote, J | 1 |
| Thomas, HC | 1 |
| Sherlock, S | 1 |
| Wilkinson, SP | 1 |
| Moodie, H | 1 |
| Arroyo, VA | 1 |
| Arnman, R | 1 |
| Iwarson, S | 1 |
| Olsson, R | 1 |
| Lai, JC | 1 |
| Silk, DB | 1 |
| Mutimer, DJ | 1 |
| Elias, E | 1 |
| Pereira, LM | 1 |
| Hayllar, KM | 2 |
| Tredger, JM | 1 |
| McIntyre, N | 1 |
| Rolando, N | 2 |
| de la Mata, M | 1 |
| Meager, A | 1 |
| Daniels, HM | 1 |
| Nouri-Aria, KT | 1 |
| Goka, AK | 1 |
| Alexander, GJ | 2 |
| Forbes, A | 1 |
| Scaiola, A | 1 |
| MacMathuna, P | 1 |
| Gove, CD | 1 |
| O'Grady, JG | 2 |
| O'Brien, CJ | 1 |
| Pucknell, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Safety and Efficacy of Steroids in the Management of Fulminant Hepatic Failure Due to Hepatitis A Virus in the Pediatric Age Group[NCT02375867] | Phase 4 | 33 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| A Multi-Center Trial to Study Acute Liver Failure in Adults[NCT00518440] | 3,488 participants (Actual) | Observational | 1998-01-31 | Completed | |||
| Collection of Blood and Stool Samples in Patients With Acute Hepatitis[NCT00001879] | 200 participants | Observational | 1999-03-31 | Completed | |||
| 13C-Methacetin Breath Test for the Prediction of Outcome in in Acute Liver Injury or Acute Liver Failure[NCT02786836] | Phase 2/Phase 3 | 76 participants (Actual) | Interventional | 2016-06-10 | Completed | ||
| A Phase 2a Study to Evaluate the Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in the Treatment of Patients With Acute Liver Failure/Severe Acute Liver Injury[NCT01548690] | Phase 2 | 47 participants (Actual) | Interventional | 2012-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The relationship between the cPDR (cumulative PDR of metabolized 13C-Methacetin 20 minutes after ingestion) in single time points of MBT measurements and TFS and non-TFS (death/transplant) at Day 21. (NCT02786836)
Timeframe: The first MBT reading either on Day 1 or Day 2 and Day 21
| Intervention | percentage per hour (Mean) | |
|---|---|---|
| Day 1 or 2 MBT/transplant free survival at Day 21 | Day 1 or 2 MBT & Day 21 non-TFS | |
| 13C-Methacetin Breath Test (MBT) | 1.4 | 0.2 |
Peak PDR is the maximal percent dose recovery (PDR) rate which reflects the maximum rate of metabolism of 13C-methacetin measured as the change in 13CO2 / 12CO2 (normal carbon dioxide) ratio after ingestion of 13C-methacetin normalized using the patient's height and weight. The distributions of mean PDR Peak values were compared between TFS (transplant free survival) and non-TFS (death/transplant) at Day 21. (NCT02786836)
Timeframe: Days 1 and 21
| Intervention | percentage per hour (Mean) | |
|---|---|---|
| Mean Peak PDR for TFS subjects at Day 21 | Mean Peak PDR for non-TFS subjects at Day 21 | |
| 13C-Methacetin Breath Test (MBT) | 10.2 | 1.9 |
This outcome is similar to the peak PDR defined in the primary outcome but as a secondary we are looking at Day 1 or Day 2 peak PDR values. Peak PDR is the maximal percent dose recovery (PDR) rate which reflects the maximum rate of metabolism of 13C-methacetin measured as the change in 13CO2 / 12CO2 ratio after ingestion of 13C-methacetin normalized using the patient's height and weight. The distributions of mean PDR Peak values were compared between TFS and non-TFS (death/transplant) at Day 21. (NCT02786836)
Timeframe: The first MBT reading either on Day 1 or Day 2 and Day 21
| Intervention | percentage per hour (Mean) | |
|---|---|---|
| Day 1 or 2 MBT & Day 21 TFS | Day 1 or 2 MBT & Day 21 non-TFS | |
| 13C-Methacetin Breath Test (MBT) | 9.1 | 2.3 |
To evaluate the effect of OCR-002 on ammonia levels in patients with acute liver failure/severe acute liver injury (NCT01548690)
Timeframe: Baseline and 72 Hours
| Intervention | Percent Change (Mean) |
|---|---|
| Maximum Dose Level 3.33 g/24h | 41.2 |
| Maximum Dose Level 6.65 g/24h | 16.6 |
| Maximum Dose Level 10 g/24h | 41.8 |
| Maximum Dose Level 20g/24h | 38.4 |
To evaluate the steady state pharmacokinetic and pharmacodynamic profile of OCR-002 in patients with impaired and intact renal function using urinary phenylacetylglutamine (PAGN) as a surrogate marker (NCT01548690)
Timeframe: 24 Hours after last infusion
| Intervention | micrograms per millileter (Mean) |
|---|---|
| Maximum Dose Level 3.33 g/24h | 65.6 |
| Maximum Dose Level 6.65 g/24h | 32.2 |
| Maximum Dose Level 10 g/24h | 33.4 |
| Maximum Dose Level 20g/24h | 104.9 |
The orientation log focuses on orientation to place, time, and circumstance. There are 10 items on the orientation log, which are scored 0-3. A spontaneous correct response is awarded 3 points. A spontaneous response that is lacking or incorrect, but a correct response is provided following a logical cue is awarded 2 points. A score of 1 is given if spontaneous and cued responses are lacking or incorrect, but a correct response is provided in a recognition format. A score of 0 is given if the spontaneous, cued, or recognition format does not generate a correct answer. Scores from the 10 items are summed and the final score ranges from 0 to 30. (NCT01548690)
Timeframe: 30 Days
| Intervention | units on a scale (Mean) |
|---|---|
| Maximum Dose Level 3.33 g/24h | 23.8 |
| Maximum Dose Level 6.65 g/24h | 24.0 |
| Maximum Dose Level 10 g/24h | 24.0 |
| Maximum Dose Level 20g/24h | 24.0 |
The West Haven Criteria (WHC) for Hepatic Encephalopathy measures the severity of encephalopathy and patient's level of consciousness. The scale ranges from 0 to 4; a minimum score of 0 represents a better outcome, and a maximum total score of 4 represents a worse outcome. A score of 0 corresponds to normal consciousness and behavior and normal neurological examination. A score of 1 corresponds to mild lack of awareness, shortened attention span, and impaired addition or subtraction; mild asterixis or tremor. A score of 2 corresponds to lethargy, disorientated or inappropriate behavior, obvious asterixis; slurred speech. A score of 3 corresponds to somnolent but arousable, gross disorientation or bizarre behavior, muscle rigidity and clonus; hyperreflexia. A score of 4 corresponds to coma and decerebrate posturing. (NCT01548690)
Timeframe: 120 hours from start of infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Maximum Dose Level 3.33 g/24h | 2.4 |
| Maximum Dose Level 6.65 g/24h | 3.2 |
| Maximum Dose Level 10 g/24h | 1.6 |
| Maximum Dose Level 20g/24h | 1.8 |
To evaluate the safety and tolerability of OCR-002 in patients with acute liver failure/severe acute liver injury (NCT01548690)
Timeframe: 30 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Maximum Dose Level 3.33 g/24h | 0 |
| Maximum Dose Level 6.65 g/24h | 0 |
| Maximum Dose Level 10 g/24h | 0 |
| Maximum Dose Level 20g/24h | 0 |
17 reviews available for acetaminophen and Hepatitis, Viral, Human
| Article | Year |
|---|---|
Pathophysiology of Acute Liver Failure.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Chemical and Drug Induced Liver Injury; Drug Overdose; Fema | 2020 |
Classification and Epidemiologic Aspects of Acute Liver Failure.
Topics: Acetaminophen; Chemical and Drug Induced Liver Injury; Hepatitis, Viral, Human; Humans; Liver Failur | 2018 |
Acute Liver Failure.
Topics: Acetaminophen; Chemical and Drug Induced Liver Injury; Critical Care; Drug Overdose; Hepatitis, Auto | 2018 |
[Severe toxic acute liver failure: etiology and treatment].
Topics: Acetaminophen; Acetylcysteine; Acute Kidney Injury; Anti-Infective Agents; Blood Coagulation Disorde | 2013 |
Update in intensive care medicine: acute liver failure. Initial management, supportive treatment and who to transplant.
Topics: Acetaminophen; Antiviral Agents; Chemical and Drug Induced Liver Injury; Critical Care; Female; Hepa | 2014 |
Acute liver failure.
Topics: Acetaminophen; Ammonia; Analgesics, Non-Narcotic; Chemical and Drug Induced Liver Injury; Emergency | 2010 |
The potential of cytokines as safety biomarkers for drug-induced liver injury.
Topics: Acetaminophen; Anesthetics, Inhalation; Animals; Biomarkers; Chemical and Drug Induced Liver Injury; | 2010 |
Fulminant liver disease.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Hepatitis, Viral, Human; Humans; Liver Failure, Ac | 2003 |
Acetaminophen and the U.S. Acute Liver Failure Study Group: lowering the risks of hepatic failure.
Topics: Acetaminophen; Acute Disease; Analgesics, Non-Narcotic; Hepatitis, Viral, Human; Humans; Liver Failu | 2004 |
Epidemiology of acute liver failure.
Topics: Acetaminophen; Acetylcysteine; Analgesics, Non-Narcotic; Drug-Related Side Effects and Adverse React | 2007 |
Etiologies of acute liver failure.
Topics: Acetaminophen; Anti-Bacterial Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroi | 2008 |
Classification, etiology, and considerations of outcome in acute liver failure.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Chemical and Drug Induced Liver Injury; Drug Overdose; Hepa | 1996 |
Update in hepatology.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Hepatitis; Hepatitis, Viral, Human; Humans; Liver Cirrhosis | 1999 |
Acute liver failure; clinical features and management.
Topics: Acetaminophen; Brain Edema; Diuretics, Osmotic; Hepatitis, Viral, Human; Humans; Liver Failure, Acut | 1999 |
Acute hepatic failure: a Western perspective.
Topics: Acetaminophen; Acetylcysteine; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; He | 2000 |
Liver transplantation for fulminant hepatic failure.
Topics: Acetaminophen; Hepatitis, Viral, Human; Humans; Kidney; Liver Failure, Acute; Liver Transplantation; | 1992 |
Hepatobiliary disease: medical emergencies.
Topics: Acetaminophen; Biliary Tract Diseases; Emergencies; Halothane; Hepatic Encephalopathy; Hepatitis, Vi | 1991 |
1 trial available for acetaminophen and Hepatitis, Viral, Human
| Article | Year |
|---|---|
Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure.
Topics: Acetaminophen; Adolescent; Adult; Aged; Charcoal; Child; Clinical Trials as Topic; Female; Halothane | 1988 |
32 other studies available for acetaminophen and Hepatitis, Viral, Human
| Article | Year |
|---|---|
FGL2-MCOLN3-Autophagy Axis-Triggered Neutrophil Extracellular Traps Exacerbate Liver Injury in Fulminant Viral Hepatitis.
Topics: Acetaminophen; Animals; Autophagy; Calcium; Deoxyribonucleases; Disease Models, Animal; Extracellula | 2022 |
EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure.
Topics: Acetaminophen; Airway Management; Hepatitis, Autoimmune; Hepatitis, Viral, Human; Humans; Liver Fail | 2017 |
Acute Liver Failure of Indeterminate Etiology: A Comprehensive Systematic Approach by An Expert Committee to Establish Causality.
Topics: Acetaminophen; Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Chemical and Drug Induced Liv | 2018 |
The regulation of T-cell recruitment to the human liver during acute liver failure.
Topics: Acetaminophen; Biomarkers; Cell Adhesion; Cell Adhesion Molecules; Cell Separation; Cells, Cultured; | 2013 |
The Prescription Pattern of Acetaminophen and Non-Steroidal Anti-Inflammatory Drugs in Patients with Liver Cirrhosis.
Topics: Acetaminophen; Aged; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Chemical and Drug Induced | 2016 |
Long-term follow-up of patients with acute liver failure of indeterminate aetiology.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Budd-Chiari Syndrome; Disease Progression; Female; F | 2008 |
Recovery of awareness after hyperacute hepatic encephalopathy with "flat" EEG, severe brain edema and deep coma.
Topics: Acetaminophen; Adult; Awareness; Brain Edema; Electroencephalography; Hepatic Encephalopathy; Hepati | 2010 |
Influence of acetaminophen at therapeutic doses on surrogate markers of severity of acute viral hepatitis.
Topics: Acetaminophen; Acute Disease; Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Bilirubin; Biomarke | 2006 |
Etiologies of acute liver failure: location, location, location!
Topics: Acetaminophen; Analgesics, Non-Narcotic; Chemical and Drug Induced Liver Injury; Global Health; Hepa | 2007 |
Platelet adhesiveness to glass beads in liver disease.
Topics: Acetaminophen; Chemical and Drug Induced Liver Injury; Chronic Disease; Glass; Hemoperfusion; Hepati | 1982 |
[Does therapy for common liver diseases exist?].
Topics: Acetaminophen; Hepatitis; Hepatitis, Chronic; Hepatitis, Viral, Human; Humans; Prednisone | 1983 |
Anti-LSP antibodies in acute liver disease.
Topics: Acetaminophen; Acute Disease; Autoantibodies; Chemical and Drug Induced Liver Injury; Hepatitis, Alc | 1982 |
Bacteraemia in patients with fulminant hepatic failure.
Topics: Acetaminophen; Adolescent; Adult; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; H | 1982 |
Disturbances of lactate metabolism in patients with liver damage due to paracetamol overdose.
Topics: Acetaminophen; Adult; Chemical and Drug Induced Liver Injury; Female; Hepatitis, Viral, Human; Human | 1981 |
Circulating immune complexes in patients with fulminant hepatic failure.
Topics: Acetaminophen; Adolescent; Adult; Aged; Antigen-Antibody Complex; Chemical and Drug Induced Liver In | 1981 |
Extent of the acute phase response in fulminant hepatic failure.
Topics: Acetaminophen; Acute-Phase Reaction; Adolescent; Adult; alpha 1-Antitrypsin; Bacterial Infections; C | 1994 |
Cerebral blood flow and metabolism in fulminant liver failure.
Topics: Acetaminophen; Acetylcysteine; Adult; Blood Flow Velocity; Brain; Brain Edema; Drug Overdose; Epopro | 1994 |
Morphology of hepatic stellate cells in patients with fulminant or subfulminant hepatitis requiring liver transplantation.
Topics: Acetaminophen; Actins; Adult; Aged; Amanita; Autoimmune Diseases; Biomarkers; Cell Differentiation; | 1996 |
Plasma levels and hepatic mRNA expression of transforming growth factor-beta1 in patients with fulminant hepatic failure.
Topics: Acetaminophen; Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Blotting, Northern; Enzyme-Linked | 1997 |
Assay to detect inhibitory substances in serum of patients with acute liver failure.
Topics: Acetaminophen; Adolescent; Adult; Analgesics, Non-Narcotic; Cell Survival; Cells, Cultured; DNA; Enz | 1999 |
East meets West: acute liver failure in the global village.
Topics: Acetaminophen; Global Health; Hepatitis, Viral, Human; Humans; Liver Failure, Acute; Liver Transplan | 2000 |
Acute cholestatic hepatitis caused by a probable allergic reaction to paracetamol in an adolescent.
Topics: Acetaminophen; Acute Disease; Adolescent; Analgesics, Non-Narcotic; Bilirubin; Chemical and Drug Ind | 2001 |
Serum alpha-fetoprotein levels in patients with acute and chronic liver disease. Relation to hepatocellular regeneration and development of primary liver cell carcinoma.
Topics: Acetaminophen; Acute Disease; Adult; alpha-Fetoproteins; Carcinoma, Hepatocellular; Chronic Disease; | 1977 |
Frequency of renal impairment in paracetamol overdose compared with other causes of acute liver damage.
Topics: Acetaminophen; Acute Kidney Injury; Chemical and Drug Induced Liver Injury; Endotoxins; Hepatitis, V | 1977 |
The clinical significance of increased plasma levels of liver-synthesized coagulation factors in liver disease.
Topics: Acetaminophen; Acute Disease; Biliary Tract Diseases; Blood Coagulation Factors; Chemical and Drug I | 1977 |
Plasma short-chain fatty acids in fulminant hepatic failure.
Topics: Acetaminophen; Acute Disease; Adolescent; Adult; Creatinine; Fatty Acids, Volatile; Female; Hepatic | 1977 |
Coagulation factor V and VIII/V ratio as predictors of outcome in paracetamol induced fulminant hepatic failure: relation to other prognostic indicators.
Topics: Acetaminophen; Adolescent; Adult; Drug Overdose; Factor V; Factor VIII; Female; Hepatic Encephalopat | 1992 |
Increased elastase-alpha 1-antitrypsin complex in fulminant hepatic failure: relationship to bacterial infection and activation of coagulation.
Topics: Acetaminophen; alpha 1-Antitrypsin; Aspartate Aminotransferases; Bacterial Infections; Bilirubin; Bl | 1991 |
Tumour necrosis factor production in fulminant hepatic failure: relation to aetiology and superimposed microbial infection.
Topics: Acetaminophen; Adolescent; Adult; Bacterial Infections; Child; Female; Hepatitis, Viral, Human; Huma | 1990 |
Thrombin-antithrombin III complex in fulminant hepatic failure: evidence for disseminated intravascular coagulation and relationship to outcome.
Topics: Acetaminophen; Adolescent; Adult; Antithrombin III; Disseminated Intravascular Coagulation; Drug Ove | 1990 |
Determination of the ketone body ratio in fulminant hepatic failure.
Topics: Acetaminophen; Energy Metabolism; Hepatitis, Viral, Human; Humans; Ketone Bodies; Liver; Liver Disea | 1990 |
Early indicators of prognosis in fulminant hepatic failure.
Topics: Acetaminophen; Adult; Chemical and Drug Induced Liver Injury; Child; Drug Hypersensitivity; Halothan | 1989 |